Community Practice Connections™: Chronic Fibrosing ILDs With Progressive Phenotype—Are You Aware of the Latest Data on Diagnosis and Emerging Treatments?

Released On
August 19, 2020

Expires On
August 19, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Critical Care, Pulmonology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward pulmonologists, rheumatologists, radiologists, and critical care specialists, as well as nurses, nurse practitioners, physician assistants, and other specialists involved in the management of CF-ILD.

Program Overview

This Community Practice Connections™ program provides an in-depth review of topics covered in a July 2020 virtual symposium. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with chronic fibrosing interstitial lung disease (CF-ILD), putting recent clinical trial data into context. The program is designed both for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the radiological and histopathological patterns of fibrosis in chronic fibrosing ILDs and their role in defining disease etiology and subsequent management
  • Identify key mechanisms underlying the varied forms of chronic fibrosing ILD, clinical presentation, and management
  • Improve your ability to diagnose chronic fibrosing ILDs earlier in the course of disease to allow for prompt intervention
  • Analyze the implications of recent and ongoing clinical research for the treatment of chronic fibrosing ILDs.

Faculty

Steven Nathan, MD

Steven Nathan, MD

Medical Director, Advanced Lung Disease and Lung Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Elana J. Bernstein, MD, MSc

Elana J. Bernstein, MD, MSc

Assistant Professor of Medicine
Program Director, Columbia University Medical Center/New York-Presbyterian Scleroderma Program
Division of Rheumatology, Department of Medicine
Columbia University Vagelos College of Physicians and Surgeons
Columbia University Irving Medical Center
New York, NY

Christopher S. King, MD, FACP, FCCP

Christopher S. King, MD, FACP, FCCP

Medical Director, Transplant and Advanced Lung Disease Critical Care Program
Inova Fairfax Hospital
Falls Church, VA

Ami N. Rubinowitz, MD

Ami N. Rubinowitz, MD

Associate Professor of Radiology and Biomedical Imaging
Yale School of Medicine, Thoracic Imaging Section
Yale New Haven Hospital
New Haven, CT

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.00. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

Steven Nathan, MD

  • Grant Research Support: F. Hoffman-La Roche/Genentech Inc, Boehringer Ingelheim Pharmaceuticals Inc;
  • Consultant: F. Hoffman-La Roche/Genentech Inc, Boehringer Ingelheim Pharmaceuticals Inc, United Therapeutics Corp, Belleropharm LLC;
  • Speakers Bureau: F. Hoffman-La Roche/Genentech Inc, Boehringer Ingelheim Pharmaceuticals Inc.

Elana J. Bernstein, MD, MSc

  • Grant Research Support: Boehringer Ingelheim Pharmaceuticals Inc;
  • Consultant: Boehringer Ingelheim Pharmaceuticals Inc.

Christopher S. King, MD, FACP, FCCP

  • Speakers Bureau: Boehringer Ingelheim Pharmaceuticals Inc, Genentech Inc

Ami N. Rubinowitz, MD

  • No relevant financial relationships with commercial interest to disclose.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/ Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.
Certificates will be emailed to the participant

 

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.